Table 2.
Baseline characteristics of 50 NDMM patients.
| Characteristics | All patients (%) | Hgb > 90 g/L (%) | Hgb ≤ 90 g/L (%) | p |
|---|---|---|---|---|
| No. of patients | 50 | 24 (48.0%) | 26 (52.0%) | |
| Sex | ||||
| Male | 29 (58%) | 11 (57.1%) | 9(58.1%) | |
| Female | 21 (42%) | 13 (42.9%) | 17(41.9%) | |
| Age/median; range | 56 (33–68) | 53 (36–68) | 56 (33–68) | 0.654 |
| BM-infiltration (%) median; range | 60 (5–90) | 30 (5–85) | 65 (8–90) | < 0.01 |
| Ig isotype | ||||
| IgG | 23 (46.0%) | 10(41.7%) | 13 (50.0%) | |
| IgA | 12 (24.0%) | 6 (25.0%) | 6 (23.1%) | |
| IgD | 2 (4.0%) | 2 (8.3%) | 0 (0.0%) | |
| Light chain | 10 (20.0%) | 4 (16.7%) | 6 (23.1%) | |
| Non-secretory | 3 (6.0%) | 2 (8.3%) | 1 (3.8%) | |
| RISS stage | 0.028 | |||
| I | 5 (10.0%) | 4 (25.0%) | 1 (4.3%) | |
| II | 10 (20.0%) | 5 (31.3%) | 5 (21.8%) | |
| III | 24 (48.0%) | 7 (43.7%) | 17 (73.9%) | |
| DS stage | 0.235 | |||
| I | 1 (2.0%) | 1 (6.3%) | 0 (0.0%) | |
| II | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| III | 38 (76.0%) | 15 (93.7%) | 23(100.0%) | |
| MBD | < 0.0001 | |||
| 0–2 | 14 (28.0%) | 13 (54.2%) | 1(3.8%) | |
| 3–4 | 36 (72.0%) | 11 (45.8%) | 25 (96.2%) | |
| Hemoglobin (g/L) median; range | 88 (44–161) | 109 (91–161) | 69 (44–89) | |
RISS Revised international staging system, DS Durie Salmon, MBD myeloma bone disease.